Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Interleukin (IL)-1 impairs insulin secretion and induces β-cell apoptosis. Pancreatic β-cell IL-1 expression is increased and interleukin-1 receptor antagonist (IL-1Ra) expression reduced in patients with type 2 diabetes. Treatment with recombinant IL-1Ra improves glycemia and β-cell function and reduces inflammatory markers in patients with type 2 diabetes. Here we investigated the durability of these responses. RESEARCH DESIGN AND METHODS: Among 70 ambulatory patients who had type 2 diabetes, A1C >7.5%, and BMI >27 kg/m2 and were randomly assigned to receive 13 weeks of anakinra, a recombinant human IL-1Ra, or placebo, 67 completed treatment and were included in this double-blind 39-week follow-up study. Primary outcome was change in β-cell function after anakinra withdrawal. Analysis was done by intention to treat. RESULTS: Thirty-nine weeks after anakinra withdrawal, the proinsulin-to-insulin (PI/I) ratio but not stimulated C-peptide remained improved (by −0.07 [95% CI −0.14 to −0.02], P = 0.011) compared with values in placebo-treated patients. Interestingly, a subgroup characterized by genetically determined low baseline IL-1Ra serum levels maintained the improved stimulated C-peptide obtained by 13 weeks of IL-1Ra treatment. Reductions in C-reactive protein (−3.2 mg/l [−6.2 to −1.1], P = 0.014) and in IL-6 (−1.4 ng/l [−2.6 to −0.3], P = 0.036) were maintained until the end of study. CONCLUSIONS: IL-1 blockade with anakinra induces improvement of the PI/I ratio and markers of systemic inflammation lasting 39 weeks after treatment withdrawal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“lower levels of IL-1Ra may predict who maintains better β-cell function after an intervention to decrease islet inflammation70.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [70]
In the citing paper
“This treatment approach for type 2 diabetes is promising, as the improvement in levels of glucose and inflammatory markers was long-lasting110.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [110]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114 · cited 1×
“Secondary outcomes included change between baseline and 52 weeks in IL-6, C-reactive protein (CRP), insulin requirements, A1C, and the homeostasis model assessment– insulin sensitivity index (HOMA-Si) (18).”
Backgroundβ-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962 · cited 1×
“During the course of the disease beta-cell function progressively declines irrespective of treatment with glucose-lowering drugs (2-4).”
BackgroundU.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798 · cited 6×
“At baseline, and at 13 and 52 weeks, beta-cell secretory function was assessed by the fasting PI/I ratio and by a 2-hour oral glucose-tolerance test directly followed by a 12-minute intravenous glucose, glucagon and arginine stimulation test as described previously (16).”
BackgroundMethodResultInfluentialSelf-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Self-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
Self-citationDiagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s43 · Cited by 924
Increased Number of Islet-Associated Macrophages in Type 2 Diabetes
Ehses, J. A., Perren, A., Eppler, E., Ribaux, P., Pospisilik, J. A., Maor-Cahn, R., Gueripel, X., Ellingsgaard, H., Schneider, M. K. J., Biollaz, G., et al. (2007) · Diabetes · doi:10.2337/db06-1650 · Cited by 783 · cited 1×
“IL-1 production could thus originate from the betacell (7) or from macrophages infiltrating the islets (23) as the IL-1B gene is overexpressed in blood monocytes from patients with type 2 diabetes (24).”
BackgroundSelf-citation
Cited by
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
“Mechanisms by which inflammasome activation and elevated IL-1 b may drive the progression from obesity to T2D are reviewed elsewhere in detail (Schroder et al., 2010).”
InfluentialType 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
“Of note, the improvement in insulin secretion lasted 39 weeks following the withdrawal of IL-1RA treatmen”
BackgroundSelf-citationSterile inflammation: sensing and reacting to damage
Chen, G. Y., & Nuñez, G. (2010) · Nature Reviews Immunology · doi:10.1038/nri2873 · Cited by 3,051
“This treatment approach for type 2 diabetes is promising, as the improvement in levels of glucose and inflammatory markers was long-lastin”
BackgroundCaspase Functions in Cell Death and Disease
McIlwain, D. R., Berger, T., & Mak, T. W. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008656 · Cited by 2,594
“Excessive caspase-1 activity has thus been implicated in T2D etiology.”
MethodInfluentialInterleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Inflammation in obesity, diabetes, and related disorders
Rohm, T. V., Meier, D. T., Olefsky, J. M., & Donath, M. Y. (2022) · Immunity · doi:10.1016/j.immuni.2021.12.013 · Cited by 2,066
Self-citationInflammation as a link between obesity, metabolic syndrome and type 2 diabetes
Esser, N., Legrand-Poels, S., Piette, J., Scheen, A. J., & Paquot, N. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.04.006 · Cited by 1,981
“[71] Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T.”
BackgroundTreating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Tsalamandris, S., Antonopoulos, A. S., Oikonomou, E., Papamikroulis, G.-A., Vogiatzi, G., Papaioannou, S., Deftereos, S., & Tousoulis, D. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.33.1 · Cited by 1,381
Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes
Zatterale, F., Longo, M., Naderi, J., Raciti, G. A., Desiderio, A., Miele, C., & Beguinot, F. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2019.01607 · Cited by 1,180
“The follow-up study on the same population proves that 39 weeks after the last IL-1R antagonist administration, β-cell insulin secretion is still increased and CRP decreased (Larsen et al., 2009).”
BackgroundThe NLRP3 Inflammasome: A Sensor for Metabolic Danger?
Schroder, K., Zhou, R., & Tschopp, J. (2010) · Science · doi:10.1126/science.1184003 · Cited by 1,134
Anti-inflammatory Agents: Present and Future
Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095
“A single-nucleotide polymorphism (SNP) is associated with lower circulating levels of IL-1Ra (Larsen et al., 2009; Rafiq et al., 2007) and a concomitant increase in type 2 diabetes (Larsen et al.”
The intestinal microbiota fuelling metabolic inflammation
Tilg, H., Zmora, N., Adolph, T. E., & Elinav, E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0198-4 · Cited by 1,089
A clinical perspective of IL‐1β as the gatekeeper of inflammation
Dinarello, C. A. (2011) · European Journal of Immunology · doi:10.1002/eji.201141550 · Cited by 775
Molecular Mechanisms Linking Oxidative Stress and Diabetes Mellitus
Yaribeygi, H., Sathyapalan, T., Atkin, S. L., & Sahebkar, A. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/8609213 · Cited by 685
Targeting inflammation in the treatment of type 2 diabetes: time to start
Donath, M. Y. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4275 · Cited by 690
Self-citationUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Blevins, H. M., Xu, Y., Biby, S., & Zhang, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.879021 · Cited by 587
Todd, J. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.04.001 · Cited by 560
“The balance between the functions of T effector and Treg cells appears to be important in human T1D (Lawson et al., 2008; Long et al., 2009).”
BackgroundTreating inflammation by blocking interleukin-1 in humans
Dinarello, C. A., & van der Meer, J. W. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.008 · Cited by 549
Immunometabolism: an emerging frontier
Mathis, D., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2922 · Cited by 515
“Small clinical trials report positive outcomes following selective blockade of IL-1 receptor type 1, either with specific antibodies or recombinant IL-1 receptor antagonis”
BackgroundThe role of infiltrating immune cells in dysfunctional adipose tissue
Guzik, T. J., Skiba, D. S., Touyz, R. M., & Harrison, D. G. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx108 · Cited by 445
A review of the evidence for pathogenic mechanisms that may link periodontitis and diabetes
Taylor, J. J., Preshaw, P. M., & Lalla, E. (2013) · Journal of Clinical Periodontology · doi:10.1111/jcpe.12059 · Cited by 425
“2010) and for cytokine blockade in therapy for T2DM (Larsen et al. 2009).”
BackgroundNegash, A. A., Ramos, H. J., Crochet, N., Lau, D. T. Y., Doehle, B., Papic, N., Delker, D. A., Jo, J., Bertoletti, A., Hagedorn, C. H., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003330 · Cited by 414
“Interventions that target IL-1b or inflammasome components [50–52] could thus serve as therapeutic applications to mitigate HCV-induced hepatic inflammation and disease, particularly where antiviral agents have failed.”
BackgroundRomeo, G. R., Lee, J., & Shoelson, S. E. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.241869 · Cited by 382
“secretory profile though reducing markers of systemic inflammation.(57) The beneficial effects on β-cell secretion”
Inflammation as a Link between Obesity and Metabolic Syndrome
Emanuela, F., Grazia, M., Marco, D. R., Maria Paola, L., Giorgio, F., & Marco, B. (2012) · Journal of Nutrition and Metabolism · doi:10.1155/2012/476380 · Cited by 357
“The improvement in β-cell function could be a consequence of inhibited IL-1 signaling and not only of improved glycaemia per se [62].”
BackgroundAnti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes
Everett, B. M., Donath, M. Y., Pradhan, A. D., Thuren, T., Pais, P., Nicolau, J. C., Glynn, R. J., Libby, P., & Ridker, P. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.002 · Cited by 329
Self-citationInflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity
Donath, M. Y., Dalmas, É., Sauter, N. S., & Böni-Schnetzler, M. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.001 · Cited by 338
“…while the opposite holds true for its insulin sensitizing effects and for its effect on GLP-1-mediated insulin secretion (Carey et al., 2006; Jansson and Wallenius, 2007; Lazar, 2005; Mooney, 2007; Pedersen and Febbraio, 2007; Sabio et al., 2008; Weigert et al., 2007; Wunderlich et al., 2010).”
BackgroundSelf-citationIslet Inflammation Impairs the Pancreatic β-Cell in Type 2 Diabetes
Donath, M. Y., Böni-Schnetzler, M., Ellingsgaard, H., & Ehses, J. A. (2009) · Physiology · doi:10.1152/physiol.00032.2009 · Cited by 330
Self-citationRole of IL-1β in type 2 diabetes
Dinarello, C. A., Donath, M. Y., & Mandrup-Poulsen, T. (2010) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32833bf6dc · Cited by 327
Self-citationInterleukin-33 Induces Protective Effects in Adipose Tissue Inflammation During Obesity in Mice
Miller, A. M., Asquith, D. L., Hueber, A. J., Anderson, L. A., Holmes, W. M., McKenzie, A. N., Xu, D., Sattar, N., McInnes, I. B., & Liew, F. Y. (2010) · Circulation Research · doi:10.1161/circresaha.110.218867 · Cited by 324
IL-1 Blockade in Autoinflammatory Syndromes
Jesus, A. A., & Goldbach-Mansky, R. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-061512-150641 · Cited by 326
Macrophage functions in lean and obese adipose tissue
Thomas, D., & Apovian, C. (2017) · Metabolism · doi:10.1016/j.metabol.2017.04.005 · Cited by 316
The IL-1β phenomena in neuroinflammatory diseases
Mendiola, A. S., & Cardona, A. E. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1732-9 · Cited by 303
“…human receptor antagonist for IL-1R1) or neutralization of IL-1b by gevokizumab (monoclonal IgG2 antibody against IL-1b) improves pancreatic b-islet cell function and glycemia, and reduces the load of systemic inflammatory mediators in patients (Larsen et al. 2007, 2009; Cavelti-Weder et al. 2012).”
BackgroundTargeting Interleukin-1 in Heart Disease
Van Tassell, B. W., Toldo, S., Mezzaroma, E., & Abbate, A. (2013) · Circulation · doi:10.1161/circulationaha.113.003199 · Cited by 302
Anakinra Therapy for Non-cancer Inflammatory Diseases
Cavalli, G., & Dinarello, C. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01157 · Cited by 292
Bensellam, M., Laybutt, D. R., & Jonas, J.-C. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.003 · Cited by 284
“include inflammation (Larsen et al., 2007; Larsen et al., 2009), and likely hypoxia (Bensellam”
BackgroundInfluentialThe global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation
Kolb, H., & Mandrup-Poulsen, T. (2010) · Diabetologia · doi:10.1007/s00125-009-1573-7 · Cited by 292
“The effects on beta cell function and inflammatory markers were sustained after 39 weeks [ 85 ].”
BackgroundSelf-citationEffects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes
Cavelti-Weder, C., Babians-Brunner, A., Keller, C., Stahel, M. A., Kurz-Levin, M., Zayed, H., Solinger, A. M., Mandrup-Poulsen, T., Dinarello, C. A., & Donath, M. Y. (2012) · Diabetes Care · doi:10.2337/dc11-2219 · Cited by 294
“Of note, because the IL-1 receptor antagonist used in an earlier trial in type 2 diabetes (5,6) blocks receptor binding and signaling in response to both IL-1a and -b, this is the first study to show that specific neutralization of IL-1b yields similar effects.”
Self-citationInflammatory lipid mediators in adipocyte function and obesity
Iyer, A., Fairlie, D. P., Prins, J. B., Hammock, B. D., & Brown, L. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.264 · Cited by 285
Why not treat human cancer with interleukin-1 blockade?
Dinarello, C. A. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9229-0 · Cited by 277
“[53] As stated above, the same polymorphism is associated with reduced survival in patients with colon carcinoma compared with those with the wild-type allele.”
BackgroundSensing damage by the NLRP3 inflammasome
Leemans, J. C., Cassel, S. L., & Sutterwala, F. S. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01043.x · Cited by 281
“beneficial effect was sustained for 39 weeks following treatment withdrawal (92).”
Takiishi, T., Gysemans, C., Bouillon, R., & Mathieu, C. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.02.013 · Cited by 270
“primarily to insulin resistance, vitamin D may also improve insulin sensitivity and bcell function by directly modulating the generation and effects of inflammatory cytokines, as discussed previously.(155)”
BackgroundIL‐1: Discoveries, controversies and future directions
Dinarello, C. A. (2010) · European Journal of Immunology · doi:10.1002/eji.201040319 · Cited by 268
Anti-inflammatory Agents in the Treatment of Diabetes and Its Vascular Complications
Pollack, R. M., Donath, M. Y., LeRoith, D., & Leibowitz, G. (2016) · Diabetes Care · doi:10.2337/dcs15-3015 · Cited by 262
“function; these beneficial effects persisted up to several weeks after treatment cessation (92).”
BackgroundSelf-citationShelton, R. C., & Miller, A. H. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.04.004 · Cited by 261
Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus
Christensen, D. P., Dahllöf, M., Lundh, M., Rasmussen, D. N., Nielsen, M. D., Billestrup, N., Grunnet, L. G., & Mandrup-Poulsen, T. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00021 · Cited by 261
Self-citationEsser, N., Paquot, N., & Scheen, A. J. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.974804 · Cited by 250
“IL-1 blockade with anakinra induced improvement of the proinsulin/insulin ratio and markers of systemic inflammation lasting 39 weeks after treatment withdrawal [106].”
BackgroundInflammation, Cytokines and Insulin Resistance: A Clinical Perspective
Wieser, V., Moschen, A. R., & Tilg, H. (2013) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0210-1 · Cited by 241
Blockade of interleukin 1 in type 1 diabetes mellitus
Mandrup-Poulsen, T., Pickersgill, L., & Donath, M. Y. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.271 · Cited by 237
Self-citationCytokine production by islets in health and diabetes: cellular origin, regulation and function
Donath, M. Y., Böni-Schnetzler, M., Ellingsgaard, H., Halban, P. A., & Ehses, J. A. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.12.010 · Cited by 227
Self-citationObesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences.
van Greevenbroek, M. M. J., Schalkwijk, C., & Stehouwer, C. D. A. (2013) · PubMed · Cited by 284
Igoillo-Esteve, M., Marselli, L., Cunha, D. A., Ladrière, L., Ortis, F., Grieco, F. A., Dotta, F., Weir, G. C., Marchetti, P., Eizirik, D. L., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1707-y · Cited by 227
“Moreover, IL-1ra therapy is under evaluation for the treatment of type 2 diabetes [34, 35], based on studies suggesting that high-glucose-induced IL-1β secretion by beta cells causes beta cell dysfunction and death [21].”
BackgroundInterleukin-1 (IL-1) family of cytokines: Role in Type 2 Diabetes
Banerjee, M., & Saxena, M. (2012) · Clinica Chimica Acta · doi:10.1016/j.cca.2012.03.021 · Cited by 224
Varra, F.-N., Varras, M., Varra, V.-K., & Theodosis‑Nobelos, P. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13219 · Cited by 190
“For instance, larsen et al tested the effects of anakinra therapy in two studies (319,320).”
BackgroundRole of C-Reactive Protein in Diabetic Inflammation
Stanimirovic, J., Radovanovic, J., Banjac, K., Obradovic, M., Essack, M., Zafirovic, S., Gluvic, Z., Gojobori, T., & Isenovic, E. R. (2022) · Mediators of Inflammation · doi:10.1155/2022/3706508 · Cited by 192
“Treatment of T2DM patients with IL-1 receptor blocker [184, 185] or IL-1β antibodies [186–189] reduced levels of IL-6 and CRP as markers of systemic inflammation, with simultaneous improvement of glycemia and insulin secretion.”
BackgroundWatson, N., Ding, B., Zhu, X., & Frisina, R. D. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.10.002 · Cited by 210
“…(2001) (human, plasma); Schmidt et al. (1999) (human, whole blood); Barzilay et al. (2001) (human, plasma); Han et al. (2002) (human, whole blood); Larsen et al. (2009) (human, whole blood) Cardiovascular Disease Pro-inflammatory markers, specifically CRP, play a critical role in the long term…”
Mechanisms of disease: inflammasome activation and the development of type 2 diabetes
Grant, R. W., & Dixit, V. D. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00050 · Cited by 203
“IL-1β signaling is inhibited by IL-1 receptor antagonist (IL-1RA) and decoy receptors, i.e., IL-1R2.”
BackgroundInfluentialInflammation links excess fat to insulin resistance: the role of the interleukin‐1 family
Tack, C. J., Stienstra, R., Joosten, L. A. B., & Netea, M. G. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01145.x · Cited by 193
“(91) found that a 13week treatment with the IL-1Ra anakinra was associated with sustained beneficial effects on b-cell function in those diabetes patients with low baseline IL-1Ra levels.”
BackgroundYu, M., & Levine, S. J. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.02.001 · Cited by 190
“improved 39 weeks after treatment withdrawal [112].”
Westwell-Roper, C., Dai, D. L., Soukhatcheva, G., Potter, K. J., van Rooijen, N., Ehses, J. A., & Verchere, C. B. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002854 · Cited by 190
“Inhibition of hIAPP-mediated IL-1 signaling may partially explain the improvement in b cell secretory function in type 2 diabetic patients receiving anakinra (15), and our data suggest that blockade of IL-1 signaling may also promote long-term islet graft function.”
BackgroundSelf-citationUCP1 governs liver extracellular succinate and inflammatory pathogenesis
Mills, E. L., Harmon, C., Jedrychowski, M. P., Xiao, H., Garrity, R., Tran, N. V., Bradshaw, G. A., Fu, A., Szpyt, J., Reddy, A., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00389-5 · Cited by 182
Sloan-Lancaster, J., Abu-Raddad, E., Polzer, J., Miller, J. W., Scherer, J. C., De Gaetano, A., Berg, J. K., & Landschulz, W. H. (2013) · Diabetes Care · doi:10.2337/dc12-1835 · Cited by 184
“Low baseline IL-1ra serum levels predicted better glycemic and b-cell secretory responses to anakinra treatment (14).”
BackgroundA review of the evidence for pathogenic mechanisms that may link periodontitis and diabetes
Taylor, J. J., Preshaw, P. M., & Lalla, E. (2013) · Journal of Periodontology · doi:10.1902/jop.2013.134005 · Cited by 204
“2010) and for cytokine blockade in therapy for T2DM (Larsen et al. 2009).”
BackgroundLighting the fires within: the cell biology of autoinflammatory diseases
Park, H., Bourla, A. B., Kastner, D. L., Colbert, R. A., & Siegel, R. M. (2012) · Nature Reviews Immunology · doi:10.1038/nri3261 · Cited by 174
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies
Cavalli, G., & Dinarello, C. A. (2015) · Rheumatology · doi:10.1093/rheumatology/kev269 · Cited by 171
The IL-1 Pathway in Type 2 Diabetes and Cardiovascular Complications
Herder, C., Dalmas, E., Böni-Schnetzler, M., & Donath, M. Y. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.08.001 · Cited by 168
“[109]”
BackgroundSelf-citationTherapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk
Goldfine, A. B., & Shoelson, S. E. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88884 · Cited by 172
Structure, Activation and Regulation of NLRP3 and AIM2 Inflammasomes
Sharma, M., & de Alba, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020872 · Cited by 165
“1, PYPAF1) Monocytes, neutrophils, dendritic cells, lymphocytes, osteoblasts, and epithelial cel s Pathogen-associated molecular patterns (PAMPs) (bacteria and virus) [37–40], danger-associated molecular patterns (DAMPs) such as Monosodium urate [41], alum [42], silica [43], asbestos [43], calcium/potassium efflux [44…”
BackgroundInfluentialAnti‐inflammatory cytokines and risk of type 2 diabetes
Herder, C., Carstensen, M., & Ouwens, D. M. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12155 · Cited by 170
“The crosstalk between TGF-β1 and the anti-inflammatory cytokine IL-10 in the control of inflammation is well established [60], but there is also evidence that TGF-β1 interacts with IL-6 to support the differentiation of T-helper 17 (Th17) cells [61].”
BackgroundInfluentialIL-1 Signaling in Obesity-Induced Hepatic Lipogenesis and Steatosis
Negrin, K. A., Roth Flach, R. J., DiStefano, M. T., Matevossian, A., Friedline, R. H., Jung, D., Kim, J. K., & Czech, M. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107265 · Cited by 168
“Consistent with previous studies [20,21], IL-1Ra”
BackgroundThe Inflammasome in Atherosclerosis and Type 2 Diabetes
Masters, S. L., Latz, E., & O’Neill, L. A. J. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001902 · Cited by 169
State of the union between metabolism and the immune system in type 2 diabetes
Nikolajczyk, B. S., Jagannathan-Bogdan, M., Shin, H., & Gyurko, R. (2011) · Genes & Immunity · doi:10.1038/gene.2011.14 · Cited by 166
Interleukin-1 and acute brain injury
Murray, K. N., Parry-Jones, A. R., & Allan, S. M. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00018 · Cited by 166
“More promising still, in the 39 week follow up study, patients receiving IL-1Ra used 66% less insulin to return to baseline glycemic control levels (Larsen et al., 2009).”
BackgroundPathogenesis of Behçet’s disease: autoinflammatory features and beyond
Gül, A. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0502-8 · Cited by 164
Diabetes and inflammation: Fundamental aspects and clinical implications
Garcia, C., Feve, B., Ferré, P., Halimi, S., Baizri, H., Bordier, L., Guiu, G., Dupuy, O., Bauduceau, B., & Mayaudon, H. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.07.001 · Cited by 159
Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes
Salomaa, V., Havulinna, A., Saarela, O., Zeller, T., Jousilahti, P., Jula, A., Muenzel, T., Aromaa, A., Evans, A., Kuulasmaa, K., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010100 · Cited by 169
“IL-1Ra is an anti-inflammatory cytokine, but its elevation may be compensatory to the increased production of proinflammatory IL-1 beta in the pancreas, which is known to induce beta cell apoptosis and impair insulin secretion [28], [34].”
BackgroundXiao, S., Liu, C., Chen, M., Zou, J., Zhang, Z., Cui, X., Jiang, S., Shang, E., Qian, D., & Duan, J. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-10174-w · Cited by 169
Adipokines as Drug Targets in Diabetes and Underlying Disturbances
Andrade-Oliveira, V., Câmara, N. O. S., & Moraes-Vieira, P. M. (2015) · Journal of Diabetes Research · doi:10.1155/2015/681612 · Cited by 166
“Indeed the administration of anti-TNF antibodies in mice resulted in reduced inflammation and the consequent protection against dietinduced obesity and insulin resistance [102, 103].”
BackgroundAdipose Tissue-Resident Immune Cells in Obesity and Type 2 Diabetes
Lu, J., Zhao, J., Meng, H., & Zhang, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01173 · Cited by 156
“Therefore, it is not surprising that targeting some molecules that can control the activity of immune cells, such as interleukin (IL)-1 (14) and tumor necrosis factor (TNF) α (15), has been reported to be effective in diminishing diabetes progression.”
Backgroundvan Asseldonk, E. J. P., Stienstra, R., Koenen, T. B., Joosten, L. A. B., Netea, M. G., & Tack, C. J. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2992 · Cited by 155
“It has been suggested that IL-1Ra levels at baseline determine the effects of anakinra treatment, with those with the lowest level showing the highest response (25).”
BackgroundInterleukin-1 Receptor Antagonist: A New Therapy for Type 2 Diabetes Mellitus
Akash, M. S. H., Shen, Q., Rehman, K., & Chen, S. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23057 · Cited by 170
Diabetes is a proinflammatory state: a translational perspective
Devaraj, S., Dasu, M. R., & Jialal, I. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.44 · Cited by 148
A Genomic Approach to Human Autoimmune Diseases
Pascual, V., Chaussabel, D., & Banchereau, J. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101221 · Cited by 146
Mechanisms of Macrophage Polarization in Insulin Signaling and Sensitivity
Orliaguet, L., Dalmas, E., Drareni, K., Venteclef, N., & Alzaid, F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00062 · Cited by 144
Lactoferrin in aseptic and septic inflammation
Lepanto, M. S., Rosa, L., Paesano, R., Valenti, P., & Cutone, A. (2019) · Molecules · doi:10.3390/molecules24071323 · Cited by 147
“Among these, some clinical trials were conducted using anakinra (Kineret; Amgen), a recombinant human IL-1 receptor antagonist, able to either improve glycemia and beta cells’ secretory function as well as to down-regulate systemic inflammation markers [147,148].”
MethodBlocking interleukin-1β in acute and chronic autoinflammatory diseases
Dinarello, C. A. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02313.x · Cited by 164
“During the anakinra trial, it was noticed that clinical responses to anakinra correlated with baseline serum IL-1Ra levels [55], in that levels were significantly lower in patients responding to anakinra than in nonresponders.”
BackgroundInfluentialComparison of non-crystalline silica nanoparticles in IL-1β release from macrophages
Sandberg, W. J., Låg, M., Holme, J. A., Friede, B., Gualtieri, M., Kruszewski, M., Schwarze, P. E., Skuland, T., & Refsnes, M. (2012) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-9-32 · Cited by 142
“Partly based on the successful treatment with IL-1β receptor antagonists, the NALP3 inflammasome is suggested to have an important pathogenic role in several inflammatory diseases including gout, type 2 diabetes and cardiovascular disease [15-21].”
BackgroundCalvo, S. S.-C., Bharath, L. P., Pugh, G. H., SantaCruz-Calvo, L., Lenin, R. R., Lutshumba, J., Liu, R., Bachstetter, A. D., Zhu, B., & Nikolajczyk, B. S. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00575-1 · Cited by 161
Macrophages and islet inflammation in type 2 diabetes
Eguchi, K., & Manabe, I. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12168 · Cited by 135
“A follow-up study demonstrated that the reduced proinsulin-to-insulin ratio lasted 39 weeks after the treatment withdrawal [55].”
BackgroundDiabetes and Sepsis: Risk, Recurrence, and Ruination
Frydrych, L. M., Fattahi, F., He, K., Ward, P. A., & Delano, M. J. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00271 · Cited by 158
“Since these patients developed symptoms and signs of a systematic inflammatory reaction during treatment, subsequent research focused on blocking IL-1 during sepsis by using anakinra, a naturally occurring IL-1RA.”
BackgroundInfluentialNLRP3 inflammasome as a potential treatment in ischemic stroke concomitant with diabetes
Hong, P., Gu, R., Li, F., Xiong, X., Liang, W., You, Z.-J., & Zhang, H. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1498-0 · Cited by 148
Ruscitti, P., Masedu, F., Alvaro, S., Airò, P., Battafarano, N., Cantarini, L., Cantatore, F. P., Carlino, G., D'Abrosca, V., Frassi, M., et al. (2019) · PLOS Medicine · doi:10.1371/journal.pmed.1002901 · Cited by 135
Carstensen, M., Herder, C., Kivimäki, M., Jokela, M., Roden, M., Shipley, M. J., Witte, D. R., Brunner, E. J., & Tabák, A. G. (2010) · Diabetes · doi:10.2337/db09-1199 · Cited by 137
“A double-blind, parallelgroup trial of 70 patients with type 2 diabetes showed that the administration of exogenous IL-1Ra (anakinra) improved glycemia, -cell function, and surrogate markers of systemic inflammation (13,14).”
BackgroundPoulsen, M. M., Fjeldborg, K., Ørnstrup, M. J., Kjær, T. N., Nøhr, M. K., & Pedersen, S. B. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.12.024 · Cited by 143
IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus
Peiró, C., Lorenzo, Ó., Carraro, R., & Sánchez‐Ferrer, C. F. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00363 · Cited by 159
“…treatment withdrawal, showed not only a maintained reduction in inflammatory markers but also a persistent improvement in β-cell function, as expressed by the lower proinsulin/insulin ratio in the formerly anakinra-treated patients as compared with those in the placebo group (Larsen et al., 2009).”
ResultDisease-associated amyloid and misfolded protein aggregates activate the inflammasome
Masters, S. L., & O'Neill, L. A. J. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.005 · Cited by 145
Targeting IL-1β in disease; the expanding role of NLRP3 inflammasome
Mitroulis, I., Skendros, P., & Ritis, K. (2010) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2010.03.005 · Cited by 149
“Recently, the same group reported sustained improvement in βcell function and inflammatory markers for 39 weeks after treatment withdrawal [70].”
BackgroundRuscitti, P., Cipriani, P., Di Benedetto, P., Liakouli, V, Berardicurti, O., Carubbi, F., Ciccia, F., Alvaro, S., Triolo, G., & Giacomelli, R. (2015) · Clinical and Experimental Immunology · doi:10.1111/cei.12667 · Cited by 126
Metadata
- Authors
- Larsen, C. M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y., & Mandrup-Poulsen, T.
- Affiliations
- Hagedorn Research Institute and Steno Diabetes Center, Gentofte, Denmark;
- University Hospital Zurich (CH)
- Lund University (SE)
- University of Copenhagen (DK)
- Corresponding author
- Mandrup-Poulsen, Thomas
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-06-19
- Volume
- 32
- Issue
- 9
- Pages
- 1663-1668
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2732140
- OpenAlex
- W2137334382
- Cited by
- 401
- References
- 28
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 27 · 2023: 15 · 2022: 14 · 2021: 28 · 2020: 16 · 2019: 21 · 2018: 11 · 2017: 23 · 2016: 21 · 2015: 27 · 2014: 36 · 2013: 42 · 2012: 32
- FWCI
- 35.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- interleukin-1 receptor antagonist, anakinra, type 2 diabetes, beta-cell function, insulin secretion, beta-cell apoptosis, IL-1 blockade, C-peptide, proinsulin/insulin ratio, C-reactive protein, interleukin-6, systemic inflammation, treatment withdrawal, glycemic control
- MeSH terms
- Diabetes Mellitus, Type 2, Female, Humans, Male, Antirheumatic Agents, Insulin-Secreting Cells, Interleukin 1 Receptor Antagonist Protein, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.